Nathalie Boyer

9.6k total citations
115 papers, 7.1k citations indexed

About

Nathalie Boyer is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Nathalie Boyer has authored 115 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Hepatology, 95 papers in Epidemiology and 12 papers in Rheumatology. Recurrent topics in Nathalie Boyer's work include Hepatitis C virus research (101 papers), Hepatitis B Virus Studies (78 papers) and Liver Disease Diagnosis and Treatment (75 papers). Nathalie Boyer is often cited by papers focused on Hepatitis C virus research (101 papers), Hepatitis B Virus Studies (78 papers) and Liver Disease Diagnosis and Treatment (75 papers). Nathalie Boyer collaborates with scholars based in France, United States and Switzerland. Nathalie Boyer's co-authors include Patrick Marcellin, Tarik Asselah, Dominique Valla, Claude Degott, Corinne Castelnau, Michèle Martinot‐Peignoux, Marie–Pierre Ripault, Pierre Bédossa, Rami Moucari and Michelle Martinot-Peignoux and has published in prestigious journals such as Journal of the American Chemical Society, Gastroenterology and PLoS ONE.

In The Last Decade

Nathalie Boyer

114 papers receiving 6.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathalie Boyer France 43 6.3k 6.2k 620 554 359 115 7.1k
Donald M. Jensen United States 36 3.7k 0.6× 3.7k 0.6× 386 0.6× 594 1.1× 260 0.7× 114 4.8k
Savino Bruno Italy 38 5.9k 0.9× 5.7k 0.9× 407 0.7× 625 1.1× 325 0.9× 133 7.0k
Robert Reindollar United States 17 6.7k 1.1× 5.9k 1.0× 679 1.1× 902 1.6× 329 0.9× 34 7.2k
Kenneth Koury United States 14 6.3k 1.0× 5.6k 0.9× 644 1.0× 854 1.5× 296 0.8× 29 6.8k
George Marinos Australia 25 7.0k 1.1× 6.2k 1.0× 753 1.2× 924 1.7× 387 1.1× 63 8.0k
Fernando Lopes Gonçales Brazil 15 5.7k 0.9× 5.0k 0.8× 563 0.9× 757 1.4× 260 0.7× 42 6.1k
Antonina Smedile Italy 41 6.6k 1.1× 6.7k 1.1× 413 0.7× 592 1.1× 502 1.4× 199 8.1k
Paul J. Pockros United States 50 6.5k 1.0× 6.2k 1.0× 650 1.0× 1.1k 1.9× 493 1.4× 190 8.5k
Hitomi Sezaki Japan 41 6.3k 1.0× 6.1k 1.0× 504 0.8× 561 1.0× 559 1.6× 276 7.5k
Akihiro Matsumoto Japan 37 3.1k 0.5× 3.3k 0.5× 424 0.7× 353 0.6× 370 1.0× 132 4.4k

Countries citing papers authored by Nathalie Boyer

Since Specialization
Citations

This map shows the geographic impact of Nathalie Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathalie Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathalie Boyer more than expected).

Fields of papers citing papers by Nathalie Boyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathalie Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathalie Boyer. The network helps show where Nathalie Boyer may publish in the future.

Co-authorship network of co-authors of Nathalie Boyer

This figure shows the co-authorship network connecting the top 25 collaborators of Nathalie Boyer. A scholar is included among the top collaborators of Nathalie Boyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathalie Boyer. Nathalie Boyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loureiro, Dimitri, Issam Tout, Ahmad Sleiman, et al.. (2022). Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis. Hepatology. 77(4). 1348–1365. 40 indexed citations
2.
Tout, Issam, Dimitri Loureiro, Abdellah Mansouri, et al.. (2020). Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. Journal of Hepatology. 73(2). 409–422. 100 indexed citations
3.
Estrabaud, Emilie, Ivan Bièche, Fabrice Carrat, et al.. (2015). IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. PLoS ONE. 10(4). e0121395–e0121395. 9 indexed citations
4.
Kutala, B., Jérémie Guedj, Tarik Asselah, et al.. (2014). Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease. Antimicrobial Agents and Chemotherapy. 59(2). 803–810. 9 indexed citations
5.
6.
Laouenan, Cédric, Jérémie Guedj, Gilles Peytavin, et al.. (2014). A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. CPT Pharmacometrics & Systems Pharmacology. 4(1). 37–40. 4 indexed citations
7.
Martinot-Peignoux, Michelle, Martine Lapalus, Cédric Laouenan, et al.. (2013). Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. Journal of Clinical Virology. 58(2). 401–407. 56 indexed citations
8.
Lada, Olivier, Marie-George Lapalus, Rami Moucari, et al.. (2012). 447 IL28B POLYMORPHISM IS NOT ASSOCIATED WITH RESPONSE TO CONVENTIONAL INTERFERON TREATMENT AND HBSAG SEROCLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS. Journal of Hepatology. 56. S177–S177. 1 indexed citations
9.
Martinot-Peignoux, Michelle, Rami Moucari, Laurence Leclere, et al.. (2010). 725 QUANTITATIVE HBSAG: A NEW SPECIFIC MARKER FOR THE DIAGNOSIS OF HBSAG INACTIVE CARRIAGE. Journal of Hepatology. 52. S282–S282. 20 indexed citations
10.
Moucari, Rami, Michelle Martinot-Peignoux, Vincent Mackiewicz, et al.. (2009). Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a. Antiviral Therapy. 14(8). 1183–1188. 59 indexed citations
11.
Moucari, Rami, Tarik Asselah, Dominique Cazals‐Hatem, et al.. (2007). Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis. Gastroenterology. 134(2). 416–423. 417 indexed citations
12.
Marcellin, Patrick, Tarik Asselah, & Nathalie Boyer. (2005). Treatment of chronic hepatitis B. Journal of Viral Hepatitis. 12(4). 333–345. 63 indexed citations
13.
Marcellin, Patrick, Tarik Asselah, & Nathalie Boyer. (2005). Treatment of Chronic Hepatitis B. PubMed. 55(1). 323–336. 9 indexed citations
14.
Gervais, Anne, Nathalie Boyer, & Patrick Marcellin. (2001). Tolerability of Treatments for Viral Hepatitis. Drug Safety. 24(5). 375–384. 15 indexed citations
15.
Gervais, Anne, Jacques Bernuau, A. Aupérin, et al.. (2000). Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. Journal of Hepatology. 32(2). 293–299. 96 indexed citations
16.
Habersetzer, François, Nathalie Boyer, Patrick Marcellin, et al.. (2000). A pilot study of recombinant interferon beta‐1a for the treatment of chronic hepatitis C. Liver International. 20(6). 437–441. 16 indexed citations
17.
Boyer, Nathalie, M. Pouteau, Corinne Castelnau, et al.. (1998). Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology. 27(4). 1144–1148. 29 indexed citations
18.
Marcellin, Patrick, M. Pouteau, Marie‐Anne Loriot, et al.. (1995). Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication.. Gut. 36(3). 422–426. 10 indexed citations
19.
Martinot‐Peignoux, Michèle, Patrick Marcellin, Corinne Castelnau, et al.. (1995). Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22(4). 1050–1056. 414 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donald M. Jensen Breakdown of academic impact, for papers by Savino Bruno Breakdown of academic impact, for papers by Robert Reindollar Breakdown of academic impact, for papers by Kenneth Koury Breakdown of academic impact, for papers by George Marinos Breakdown of academic impact, for papers by Fernando Lopes Gonçales Breakdown of academic impact, for papers by Antonina Smedile Breakdown of academic impact, for papers by Paul J. Pockros Breakdown of academic impact, for papers by Hitomi Sezaki Breakdown of academic impact, for papers by Akihiro Matsumoto
Rankless by CCL
2026